| Active substance | Olorofim |
| Holder | F2G Ltd |
| Status | Running |
| Indication | invasive fungal infections in patients lacking alternative treatment options |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 18/01/2024 |
Olorofim
Last updated on 10/09/2024